(d) whether it is also a fact that all these drugs are exempted from price control;

(e) what are the basis of exemption and how such an action will help to boost indigenous production and availability at reasonable prices;

(f) whether any company has been licensed to produce these drugs; and

(g) if so, what are the names of these companies alongwith the licensed capacity and stage of manufacture of the drugs?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) to (c) The required details to the extent available will be collected and laid on the Table of the Rajya Sabha.

(d) and (e) The above drugs were exempted from price control on the basis of recommendations of the Kelkar Committee.

(f) and (g) Details of licences issued from time to time are published regularly by the Indian Investment Centre in their Monthly News Letter. Copies of the publications are available in the Parliament Library.

Verification of Purchase invoices of Bulk Drugs

1428. DR. BAPU KALDATE: Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 3599 given in the Rajya Sabha on the 29th August, 1988 and state:

(a) what is the function of leader prices of Category II formulations particularly when such prices are not applicable to the small scale sector units;

(b) what are the reason for non-verification of purchase invoices of bulk drugs while fixing the prices of formulations and why this procedure has not been adopted;

(c) whether it is a fact that non-verification of purchase invoices gives unintended benefit to formulaters and deprive the consumer from the availability of medicines at reasonable prices;

(d) the names of the bulk drugs based on which prices of formulations were fixed under DPCO, 1987 without the verification of purchase invoices;

(e) whether it is a fact that his Ministry is reviewing the situation and is refixing the prices of finished medicines based on purchase invoices; and

(f) if so, by when?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) The Drugs (Prices Control) Order, 1987 provides for fixation of ceinling prices and not leader prices.

(b) to (f) The prices of bulk drugs keep fluctuating in the open market. The Sub Committee is, therefore, guided by notified prices/weighted average prices of the concerned bulk drugs for considering in the determination of prices of formulations. However, purchase invoices are also verified wherever found necessary.

Import of Rifampicin

1429. DR. BAPU KALDATE: Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 3723 given in the Rajya Sabha on the 29th August, 1988 and state:

(a) whether it is a fact that instances of import of intermediate by producers of Reifampicin without approval of phased manufacturing programme or in contravention of phased manufacturing programme has come to the notice of his Ministry;

(b) whether it is also a fact that instances of import of Rifampicin in